Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15

Benzinga · 3d ago
Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.